Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51 results about "Cell Transdifferentiation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A naturally occurring phenomenon where terminally differentiated cells dedifferentiate to the point where they can switch CELL LINEAGES. The cells then differentiate into other cell types.
Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
InactiveUS7041507B1Eliminate needSugar derivativesMicrobiological testing/measurementProgenitorCuticle
Disclosed is an in vitro method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and / or immunological features of a glial cell. Also disclosed are such transdifferentiated cells and cell cultures derived from them. A kit for converting, in vitro, epidermal basal cells into cells having one or more morphological, physiological and / or immunological features of a glial cell is also disclosed.
Owner:CEDARS SINAI MEDICAL CENT
Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
Disclosed is a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and / or immunological features of a neural progenitor, neuronal, or glial cell by culturing a proliferating epidermal basal cell population derived from the skin of a mammalian subject; exposing the epidermal basal cell(s) to an antagonist of bone morphogenetic protein (BMP), such as fetuin, noggin, chordin, gremlin, or follistatin; and growing the cell(s) in the presence of at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and / or a segment of a human HES1 gene, or homologous non-human counterpart of either of these. Also disclosed is a transdifferentiated cell of epidermal origin and cell cultures derived therefrom. In addition, methods of using the inventive transdifferentiated cell(s) and cell cultures to identify a novel nerve growth factor or to screen a potential chemotherapeutic agent by detecting the presence or absence of an effect, in vitro, on a morphological, physiological and / or molecular biological property of the transdifferentiated cell(s) are described, as is a method of using the transdifferentiated cell(s) and cell cultures to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin. A kit useful for practicing the methods is disclosed
Owner:CEDARS SINAI MEDICAL CENT
Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
The subject invention comprises culture methods for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway. It also concerns the endocrine hormones that can be produced by such cultures, and the use of the transdifferentiated cells in the treatment of pancreatic diseases.
Owner:IXION BIOTECH
Treatment using reprogrammed mature adult cells
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.
Owner:TRISTEM TRADING CYPRUS
Methods and compositions for identifying and validating modulators of cell fate
InactiveUS20120276572A1Minimize false positiveImprove efficiencyAnimal cellsMicrobiological testing/measurementCell dedifferentiationStem cell fate
The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
Owner:CHROMOCELL CORP
Method for inducing direct reprogramming of human fibroblasts into hepatic cells by small molecules
Owner:TRANSCEND CYTOTHERAPY CO LTD
Small molecule compound combination and method for preparing vascular endothelial cells by using small molecule compound combination to induce differentiated cells
PendingCN108070549ASmall sample sizeEasy to collectArtificial cell constructsCell culture active agentsVascular endotheliumBeta-catenin
The invention discloses a small molecule compound combination and a method for preparing vascular endothelial cells by using the small molecule compound combination to induce differentiated cells. According to the method, differentiated cells are subjected to targeted induction so as to finally obtain vascular endothelial cells, wherein the targeted induction comprises: inhibiting the activity oflysine deacetylase activity, inhibiting the signaling pathway of TGF-beta, inhibiting the activity of DNA methyltransferase (DNMT), activating the signaling pathway of WNT / beta-catenin, and activatingthe signaling pathway of cAMP. According to the present invention, through the induction with the small molecule compound combination, the differentiated cells can be transdifferentiated into the vascular endothelial cells, each step can be subjected to precise quality control, and the standardized operation and the large-scale production can be conveniently achieved; and the donor source of themethod is wide, the patient himself can be served as the donor, and the vascular endothelial cells required by basic research, clinical treatment or tissue engineering production can be obtained within a short time.
Owner:深圳臻德济慈药品研发有限公司
Customized cosmetic compositions, and methods of rejuvenating and utilizing cells and/or components thereof
ActiveUS20170360693A1Improve anti-aging effectGood synergyCosmetic preparationsOrganic active ingredientsDermatologyEmbryonic stem cell
Cosmetic formulations and compositions customized and / or personalized for rejuvenation of skin and / or hair are described. The cosmetic formulations are customized and / or personalized to include an extract and / or one or more molecular components in amounts and ratios naturally produced by rejuvenated cells or by cells modified toward rejuvenation. These cells are of skin and / or hair origin that have been reprogrammed, in which the skin and / or hair cells, having been rejuvenated and / or modified from the original cell, are initially obtained from a subject for which a customized cosmetic composition is for, or from a subject representative of a person for which a customized cosmetic composition is for. Reprogramming of the skin and / or hair cells provide rejuvenated cells, embryonic stem cell-like pluripotent cells, and / or transdifferentiated or differentiated young or younger cells that have been transdifferentiated from the rejuvenated or modified cells or differentiated from the embryonic stem cell-like pluripotent cells. Methods of selecting, preparing, and formulating the customized cosmetic products are also described.
Owner:BEMY COSMETICS LLC
Method for inducing neuroblastoma cells to be differentiated to nerve cells
ActiveCN105176929AInhibit apoptosisPromote maturityNervous system cellsNerve cellsNeuroblastoma cell
The invention relates to the cell transdifferentiation technology in the field of cell research, in particular to a method for inducing neuroblastoma cells to be differentiated to nerve cells. The neuroblastoma cells are cultured for 3-7 days through an inducing culture medium, and then the nerve cells are obtained; the inducing culture medium is obtained by adding retinoic acid to a neural stem cell condition culture solution to 10 micrometers; a complete culture medium including a DMEM / F12 basic cukture mediam, B27, bFGF, EGF, heparn sodium, L-glutamine and mycillin is used for culturing the neural stem cells, the complete culture medium is replaced by a half after culturing is conducted for three days, and the replaced culture solution is the neural stem cell condition culture solution. By means of the method, the differentiation efficiency is improved, and the maturity of the cells and growth of neural synapses of nerve cells are also improved. The cell apoptosis in SH-SY5Y treated through RA can be inhibited.
Owner:SHANDONG QILU STEM CELL ENG
Methods and compositions for identifying and validating modulators of cell fate
InactiveUS8945848B2Minimize false positivesImprove throughputAnimal cellsSugar derivativesNucleotideCell dedifferentiation
The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
Owner:CHROMOCELL CORP
Cell transdifferentiation into brown adipocytes
A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting animal cells to brown adipose tissue cells can be used to treat obesity or to treat cancer by converting target cells to brown adipose tissue cells.
Owner:MIAMI UNIVERSITY
Cell transdifferentiation method
InactiveCN106282238AAchievement of transdifferentiationFermentationGenetic engineeringLentivirusCell strain
The invention discloses a cell transdifferentiation method. The cell transdifferentiation method comprises the following steps that a lentiviral expression vector is adopted to prepare a lentivirus, the sequence of the lentiviral expression vector includes a transcription factor etv2; the lentivirus is adopted to infect a target cell line, culture is performed for 5-7 days, and then transdifferentiation of the target cell line is completed. The cell transdifferentiation method adopts the lentivirus as the carrier, the transcription factor etv2 is transfected to the target cell line, then culture is performed for 5-7 days to complete the transdifferentiation of the target cell line. FACS identification of the transdifferentiated target cell line shows that about 70% of cell expression endothelial cell molecular markers CD144 are found. It is found that genes relevant to blood vessels in transdifferentiated cells are improved at different degrees through QPCR identification of the transdifferentiated target cell line. The cell transdifferentiation method can achieve target cell linetransdifferentiation, so that cells of different sources are transdifferentiated into cellsrelevant to blood vessels, and accordingly the method can be used for cell therapy.
Owner:深圳市伊思科生物科技有限公司
Application of Ascl1 in induction of transdifferentiation of astrocytes into functional neurons
The invention provides an application of Ascl1 in induction of transdifferentiation of astrocytes into functional neurons, and concretely provides a use of an achaete-scute complex homolog-like 1 (Ascl1) gene or a protein or a promoter thereof in preparation of a medicinal composition for inducing astrocytes into functional neurons, and / or in preparation of a medicinal composition for treating nervous system diseases. The application is hopeful to become an effective method for in vitro culture of neurons and generation of new neurons through stimulation in human bodies, so the Ascl1 can be widely applied in treatment of the nervous system diseases, such as neurodegenerative diseases and central nervous trumtic diseases.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
Small-molecular compound combination and method for inducing differentiated cells to prepare vascular smooth muscle cells by using small-molecular compound combination
ActiveCN108060119ASmall sample sizeEasy to collectSkeletal/connective tissue cellsCell culture active agentsBeta-cateninBasic research
The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare vascular smooth muscle cells by using the small-molecular compound combination.The small-molecular compound combination includes a first-stage small-molecular compound and a second-stage small-molecular compound used separately according to time sequence, wherein the first-stage small-molecular compound includes at least one of DNMT inhibitors and lysine deacetylases inhibitors; the second-stage small-molecular compound includes WNT / beta-catenin agonists, cAMP agonists andTG F-beta receptor inhibitors. Through staged induction of the small-molecular compounds, the differentiated cells can be differentiated into the vascular smooth muscle cells, precision quality control can be achieved in each step, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used asa donor, and the vascular smooth muscle cells needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD
Compositions and methods for treatment of mitochondrial diseases and for differentiation of cells to neurons
Methods and compositions are provided for the treatment of a mitochondrial disease in an individual with the mitochondrial disease. Aspects of the methods include administering an inhibitor of a Pumilio-like protein and / or an inhibitor of a serine / arginine-rich family of pre-mRNA splicing factor (SR) protein to a subject. Also provided are methods, compositions, systems and kits for transdifferentiating target cells to neurons, which find use in producing neurons for the development of new therapies, for experimental evaluation, as a source of lineage- and cell- specific products, and the like, for example, for use in treating human disorders of the CNS.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for inducing astrocytes to transdifferentiate into 5-hydroxytryptaminergicneuron and application
The invention relates to a method for inducing astrocytes to transdifferentiate into 5-hydroxytryptaminergicneuron and application thereof. The invention discloses a method for generating functional 5-hydroxytryptaminergicneuron by using different transcription factor combinations to induce astrocytes to be directly reprogrammed in vitro, and the obtained neurons can survive after being transplanted into the brain. Chemical small molecules are added on the basis of application of transcription factors, so that the efficiency and maturation degree of generating 5-hydroxytryptaminergicneuron canbe further improved. The 5-hydroxytryptaminergicneuron generated by the method can be used for nerve regeneration, simulation of various nervous system diseases and drug screening.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
Small-molecular compound combination and method for inducing differentiated cells to prepare chondrocytes by using small-molecular compound combination
ActiveCN108060122AEasy to standardize operationEase of mass productionSkeletal/connective tissue cellsCell culture active agentsBeta-cateninBasic research
The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare chondrocytes by using the small-molecular compound combination. The method is used for preparing the chondrocytes by directional induction of the differentiated cells. The directed induction includes inhibition of the activity of lysine deacetylase, inhibition of a signal pathway of TGF-beta, inhibition of the activity of PKC, inhibition of the activity of DNA methyltransferase, inhibition of the activity of histone methyltransferase, activation of a WNT / beta-catenin signalpathway, activation of a cAMP signal pathway and activation of an RA signal pathway; the small-molecular compound combination includes compounds for regulating and controlling the signal pathways and / or enzyme activities. Through phased induction of the small-molecular compounds, the differentiated cells can be differentiated into the chondrocytes, precision quality control can be achieved in eachstep, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the chondrocytes needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.
Owner:深圳臻德济慈药品研发有限公司
Method for degrading BCL11B protein
ActiveCN103409466APartially explain the cause of apoptosisExplain the cause of apoptosisMicrobiological testing/measurementBiological testingSpecific proteinPopulation
The invention discloses a method for degrading BCL11B protein, which is characterized by comprising the following steps: (1) obtaining Jurkat cell population capable of realizing inducible expression of a KLF4 gene; (2) expressing the KLF4 gene by adding doxycycline to promote the Jurkat cell; (3) obtaining the Jurkat cell protein and RNA of the expressed KLF4 gene; (4) detecting the SUMO conjugation of BCL11B protein obtained in the step (3) in the Jurkat cell of the expressed KLF4 gene through Western Blot detection; (5) carrying out reverse transcription synthesis on the RNA obtained in the step (3) to obtain cDNA, detecting the expression condition of the BCL11B gene by adopting real-time quantitative PCR (polymerase chain reaction) and determining that the specific protein of the BCL11B gene is degraded. The method disclosed by the invention has the advantages that a new degradation way of specific BCL11B protein is found to partially explain the apoptosis reasons of T-ALL cells to provide theoretical guidance for leukemia treatment on one hand and provide a new train of thought for realizing human T cell transdifferentiation on the other hand.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Methods for transdifferentiating cells
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Method for inducing transdifferentiation of glial cells into functional neurons and application of method
PendingCN113652402AWith normal electrophysiological functionGuaranteed maneuverabilityNervous disorderPeptide/protein ingredientsNormal tissueNeuron
The invention provides a method for inducing transdifferentiation of glial cells into functional neurons and application of the method. Specifically, the invention provides an application of a Neurog2 functional fragment, and the functional fragment can induce glial cells to form functional neuronal cells in vivo or in vitro, not only can play a transdifferentiation role in normal tissues, but also can promote nerve reconstruction of damaged nervous tissues, and is expected to become a new method for in-vivo nervous tissue repair.
Owner:NEURAGEN BIOTHERAPEUTICS (SUZHOU) CO LTD
Small-molecular compound combination and method for inducing differentiated cells to prepare osteoblasts by using small-molecular compound combination
ActiveCN108060121AEasy and accurate quality controlSmall sample sizeEpidermal cells/skin cellsCulture processOsteoblastBeta-catenin
The invention discloses a small-molecular compound combination and a method for inducing differentiated cells to prepare osteoblasts by using the small-molecular compound combination. The small-molecular compound combination includes a first-stage small-molecular compound and a second-stage small-molecular compound used in a staged manner according to time sequence, wherein the first-stage small-molecular compound includes TGF-beta receptor inhibitors, WNT / beta-catenin agonists and cAMP agonists; the second-stage small-molecular compound includes lysine deacetylases inhibitors, TGF-beta receptor inhibitors, PKC inhibitors, WNT / beta-catenin agonists and cAMP agonists. Through phased induction of the small-molecular compounds, the differentiated cells can be differentiated into the osteoblasts, precision quality control can be achieved in each step, and standardization operation and large-scale production are facilitated. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the osteoblasts needed for basic research, clinical treatment, or tissue engineering production can be obtained in a relatively short period of time.
Owner:深圳臻德济慈药品研发有限公司
Cell transdifferentiation into brown adipocytes
Owner:MIAMI UNIVERSITY
Method of cell transdifferentiation
Owner:KANEKA CORP +1
Method for integrating multi-omics data to presume key protein kinases in cell transdifferentiation
InactiveCN109536473AReduce filter rangeImprove research efficiencyTransferasesResearch efficiencyOriginal data
The invention discloses a method for integrating multi-omics data to presume key protein kinases in cell transdifferentiation. The method comprises the steps of: preparing a cell sample during whole cell transdifferentiation, dividing the cell sample into a transcriptome group and a protein phosphorylation group, and conducting omics tests separately to obtain corresponding original data of each group; pre-processing the original data, screening the protein kinases expressing significant differences through a transcriptome, and screening the protein kinases with activity significant differences and regulation significant differences through a phosphoproteome; and integrating all protein kinases with significant differences, and conducting comprehensive measure to obtain key protein kinases. The method of the invention can provide small-scale candidate kinases for the research of cell transdifferentiation mechanism, provide a guiding direction for the research of the cell transdifferentiation mechanism, greatly narrow the screening range, improve the research efficiency and the accuracy of the experiment, shorten the research and development cycle, increase the success rate of experiments, and reduce the cost of research on cell transdifferentiation mechanisms.
Owner:EZHOU INST OF IND TECH HUAZHONG UNIV OF SCI & TECH +1
Method for inducing differentiation from neuroblastoma cells to neurons
PendingCN111454904ARaise the ratioPromote maturityBioreactor/fermenter combinationsBiological substance pretreatmentsMedicineSingle cell suspension
The invention belongs to the technical field of cell transdifferentiation, and discloses a method for inducing differentiation from neuroblastoma cells to neurons. The method comprises the following steps of acquiring the neuroblastoma cells, performing incubation and dispersion treatment to obtain single cell suspension liquid, performing centrifugation for removing supernate, precipitating the cells, adding a culture solution, performing uniform mixing, and performing subculture; and performing differentiation in a differentiation culture medium to form neuroblastoma cell-neurospheres, performing crushing, performing inoculation into a culture container containing an induction culture medium, and performing differentiation culture for 3-7 days to obtain neuronal cells. According to the method for inducing differentiation from the neuroblastoma cells to the neurons, differentiation induced formation of the neurons can be accelerated, so that the proportion of the neuronal cells generated by differentiation of the neuroblastoma cells is greatly increased. Experiments show that on the third day of induction, the neuron proportion is higher than 80%, on the seventh day, the neuron proportion reaches 95%, and the cell maturity and the neurosynaptic growth of the neuronal cells are also improved.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Promoter specifically expressed in retinal Muller cell and application thereof
PendingCN114350664AHigh activityAchieve positioningMicrobiological testing/measurementFermentationRetinal DisorderPromoter
The invention provides a promoter Muller-P which is specifically expressed in a retinal Muller cell, and the sequence of the promoter Muller-P is as shown in SEQ ID NO. 1. The promoter disclosed by the invention has very strong activity of specific expression in a retinal Muller cell, and the recombinant adeno-associated virus based on the promoter has potential clinical application value in gene therapy of retinal diseases related to the Muller cell. Besides, the promoter provided by the invention can specifically express a green fluorescent protein GFP gene in the Muller cell, can realize positioning of the Muller cell and fluorescence labeling of the Muller cell, can be used for screening the Muller cell, and has potential application value in researches such as Muller cell transdifferentiation.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL
Functional fragments for reprogramming, combinations and uses thereof
PendingCN114231489AWith reprogramming functionPromotes the efficiency of transdifferentiation into neuronsNervous disorderPeptide/protein ingredientsReprogrammingBrain tumor
Functional fragments for reprogramming, combinations, and uses thereof. The invention provides a group of transcription factors and a transcription factor combination capable of synergistically promoting the transdifferentiation of glial cells and reprogramming into functional neurons or neuron-like cells, and the glial cells are reprogrammed into functional neurons or neuron-like cells by promoting the expression of the group of transcription factors in vivo or in vitro. The transcription factor can be effectively applied to repairing damage of a nervous system by transdifferentiation of glial cells or limiting deterioration of brain tumors derived from glial cells by utilizing the transdifferentiation capability of key transcription factors, and the application of the found transcription factor and the combination thereof in preparation of medicines for treating nervous system diseases.
Owner:NEURAGEN BIOTHERAPEUTICS (SUZHOU) CO LTD
A method for inducing neuroblastoma cells to differentiate into neurons
ActiveCN105176929BPromote maturityHigh differentiation efficiencyNervous system cellsNerve cellsNeuroblastoma cell
Owner:SHANDONG QILU STEM CELL ENG
Stem cell directional differentiation and cell transdifferentiation method
InactiveCN113249318AUnderstanding Differentiation Influencing Factor ConditionsBlood/immune system cellsCell culture active agentsPetri dishDirected differentiation
The invention discloses a stem cell directional differentiation and cell transdifferentiation method. The method comprises the following steps of: step 1, extracting embryonic tissues from a placenta of a young healthy pregnant woman, placing the embryonic tissues in a culture dish filled with a cell culture solution, standing for 15min, taking out the embryonic tissues after standing, cutting the embryonic tissues into pieces to obtain embryonic parent cells, and placing the parent cells in the culture dish for continuous culture. According to the method, different differentiation stimulators are adopted to perform different differentiation induction on embryonic stem cells, and directional differentiation results of the different stimulators can be explored through embryonic stem cell differentiation results, so that the directional differentiation results of the embryonic stem cells under the action of the stimulators can be known, in-vitro differentiation conditions of the embryonic stem cells can be deeply explored, the directional differentiation results and transdifferentiation results of the embryonic stem cells can be known, and scientific researchers can know specific differentiation influence factor conditions of the embryonic stem cells conveniently.
Owner:杭州憶盛医疗科技有限公司
Combination of small molecular compounds and method for preparing osteoblasts from cells induced by the combination of small molecular compounds
ActiveCN108060121BEasy and accurate quality controlSmall sample sizeEpidermal cells/skin cellsCulture processReceptor InhibitionOsteocyte
Owner:深圳臻德济慈药品研发有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com